Reading ANAB? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ANAB free→Reading ANAB? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ANAB free→NASDAQHealth CareBiotechnologySnapshot 2026-06-16
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, but management's recent track record has been unsteady, with frequent disruptive corporate changes. The company was unprofitable over the past year, so its earnings quality can't be assessed. Peer multiples imply a price about 20% below where it trades (it looks expensive on this basis); the read is fair, but weakening. If ANAB cuts guidance on the next call, that's a meaningful negative. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 2 valuation methods, at three horizons. Current price $57.61. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $60 ANAB trades at 16× p/s — 1.7× the 9× p/s peer median. The market is re-rating it beyond its own range; our $45 fair value is low-confidence here. Analysts: $50–$90. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 31% near-term growth, in line with our forecast of about 39%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted -0.17x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates.
12 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.28 → $0.14 (-49.9% / 30d). 0 raised, 3 cut, 5 covering analysts.
0 upgrades, 0 downgrades / 30d. 100% of analysts rate Buy.
0 positive, 0 negative / 30d.
Divergence: fundamentals are strong but estimates are being cut. Worth reading the recent material events.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$215.
How much price usually moves either way.
On a bad day, this stock has moved -$500.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $2,815.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
Valuation label changed from 'fair' to 'full'.
As of June 16, 2026, the valuation changed, moving from fair to full. Risk fell, indicating a decrease in the overall risk level. The sector backdrop remained a headwind, suggesting ongoing challenges in the market environment. Recent financial performance remained strong, reflecting a positive trend in earnings.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: If healthcare sector revenue growth speeds up, it may help AnaptysBio's performance. This could signal a better environment for biotech companies.
Confirms:Healthcare sector revenue growth exceeds 10% year over year.
Disproves:Healthcare sector revenue growth remains below 10% year over year.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for ANAB yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. On May 12, 2026, AnaptysBio, Inc. (“AnaptysBio”) issued a press release announcing its financial results for the three months ended March 31, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
$50.00 – $90.00 (median $75.50) · 8 analysts · as of 2026-05-15
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
ANAB AnaptysBio, Inc. | Below typical Show detailsSector percentile: 22 of 100 | full | elevated |
ABBV AbbVie | Above typical Show detailsSector percentile: 85 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 81 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 99 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 80 of 100 | expensive | moderate |
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
AnaptysBio aims to achieve over $390 million in annualized Jemperli royalties by 2029.
AnaptysBio completed the spin-off of First Tracks Biotherapeutics to focus on core operations.
AnaptysBio appointed Christopher M. Murphy as the new Chief Financial Officer.
Why it matters: The earnings report will show if AnaptysBio can improve its financial situation. Investors will look for signs of revenue growth or cost management.
Confirms one read:Earnings report shows revenue growth year over year or a reduction in losses.
Confirms the other:Earnings report shows continued losses or revenue decline year over year.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Chief Financial Officer On May 11, 2026, AnaptysBio, Inc. (the “Company”) announced that its Board of Directors (the “Board”) appointed Christopher M. Murphy as Chief Financial Officer, effective as of May 11, 2026. Mr. Murphy previously served as Chief Financial Officer for Third Harmonic Bio, Inc. from January 2024 to December 2025…
Regulation FD Disclosure. AnaptysBio, Inc. (the “Company”) has filed Form 8937 with the IRS and will also post Form 8937 information under the “Investors” section of its website at www.anaptysbio.com. The Form 8937 provides information about the dividend received by stockholders resulting from the separation and spin-off of First Tracks Biotherapeutics, Inc. (“First Tracks”) from the Company. The Form 8937 also provides guidance on how the dividend is treated by the Company’s stockholders and…
Entry into a Material Definitive Agreement. In connection with the Spin-Off, the Company and First Tracks Biotherapeutics entered into a separation and distribution agreement (the “Separation and Distribution Agreement”) and a transition services agreement (the “Transition Services Agreement”) to effect the Spin-Off. Separation and Distribution Agreement We entered into a Separation and Distribution Agreement with First Tracks Biotherapeutics before the Spin-Off that sets forth our agreements…
Completion of Acquisition or Disposition of Assets. On April 20, 2026, the Spin-Off was completed in accordance with the Separation and Distribution Agreement. The description of the Spin-Off included under the Explanatory Note of this Current Report on Form 8-K is incorporated into this